Back to Search
Start Over
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
- Source :
-
Cancer [Cancer] 2003 Dec 15; Vol. 98 (12), pp. 2592-8. - Publication Year :
- 2003
-
Abstract
- Background: The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma.<br />Methods: In the current multicenter, cooperative group study, patients with advanced prostate carcinoma whose disease progressed despite androgen deprivation therapy were treated with a combination of oral estramustine(240 mg three times per day for 5 days), 70 mg/m2 of docetaxel, and carboplatin at a dose of (area under the curve) 5. G-CSF was used to minimize the neutropenia associated with this regimen. Each cycle was repeated every 21 days.<br />Results: Forty patients were treated with a median of 7 cycles of therapy. Of the 34 evaluable patients with elevated pretreatment prostate-specific antigen (PSA) levels, 23 (68%) had a > or = 50% decline in PSA and 20 (59%) had a > or = 75% decline. Twenty-one patients had measurable disease, with 1 complete response (5%) and 10 partial responses (47%), for an overall measurable response rate of 52% (95% confidence interval [95% CI], 30-74%). The most common Grade 3 or Grade 4 toxicities (according to the National Cancer Institute Common Toxicity Criteria) included neutropenia in 23% of patients, thrombocytopenia in 13%, and fatigue in 13%. Febrile neutropenia occurred in 1 patient (3%). The overall median time to disease progression was 8.1 months (95% CI, 6-10 months) and the overall survival period was 19 months (95% CI, 13-26 months).<br />Conclusions: The combination of estramustine, docetaxel, and carboplatin with G-CSF support was found to have significant clinical activity with an acceptable toxicity profile in patients with progressive hormone-refractory prostate carcinoma.<br /> (Copyright 2003 American Cancer Society.)
- Subjects :
- Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carboplatin administration & dosage
Disease Progression
Docetaxel
Estramustine administration & dosage
Granulocyte Colony-Stimulating Factor administration & dosage
Humans
Male
Middle Aged
Prostate-Specific Antigen blood
Prostate-Specific Antigen drug effects
Prostatic Neoplasms mortality
Prostatic Neoplasms pathology
Survival Rate
Taxoids administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Neoplasms, Hormone-Dependent drug therapy
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0008-543X
- Volume :
- 98
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 14669278
- Full Text :
- https://doi.org/10.1002/cncr.11829